Cardiovascular Risk in Cirrhotic Cardiomyopathy (CRICC) - Evaluation of Cardiovascular Risk Prediction in Patients Undergoing Liver Transplantatio

Not Applicable

Recruiting

Conditions: iver cirrhosis
Cirrhotic Cardiomyopathy
Liver Transplantation
Liver cirrhosis
Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Cardiovascular - Other cardiovascular diseases

Registration Number: ACTRN12624000321549

Lead Sponsor: ational Health and Medical Reasearch Council (NHMRC) - Post graduate scholarship

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 200

Inclusion Criteria

The study population for all study arms will be drawn from the Victorian Liver Transplant Unit at Austin Health, the state-wide service and adult liver transplant centre for Victoria and Tasmania. We will aim to prospectively recruit all adult patients (>18 years) who are waitlisted for transplantation and/or undergo pre-operative dobutamine stress echocardiography as part of their cardiac assessment as per usual unit protocols.

Exclusion Criteria

During dobutamine stress echocardiography, patients who develop chest pain, significant ST segment changes or regional wall motion abnormalities during stress will be excluded.

Patients with overt heart failure, significant valvular disease, pulmonary hypertension, amyloidosis, haemochromatosis and those on renal replacement therapy will also be excluded.

Finally, patients will be excluded if an adequate retinal examination is not possible due to cataracts or narrow-angle glaucoma.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
30-day post-operative major adverse cardiovascular events (MACE) or death. MACE is defined as any episodes of acute coronary syndrome, ventricular arrhythmia, cardiac arrest or exacerbation of heart failure.[Prospective recording of MACE events and death, supplemented by retrospective chart review to ensure completeness. 30 days post transplant.];Resolution of cirrhotic cardiomyopathy post liver transplantation.[Defined as any change of a previously blunted cardiac reserve on serial dobutamine stress echocardiography. 3 months post liver transplantation.];Change of microvascular function post liver transplantation as assessed by the dynamic vessel analyser (DVA).[Using the dynamic vessel analyser (DVA) both pre and 3-months post transplant to assess for an improvement in microvascular function, as assessed by the degree of improvement in flicker-induced retinal artery dilatation (FI-RAD). 3 months post liver transplant.]

Secondary Outcome Measures